• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Streamex Corp. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    7/13/26 5:19:19 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STEX alert in real time by email
    false 0001530766 0001530766 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    July 8, 2026

    Date of Report (Date of earliest event reported)

     

    STREAMEX CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38659   26-4333375

    (State

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    165 Lincoln Ave FL 2

    Winter Park, Florida 32789

    (Address of principal executive offices) (Zip Code)

     

    (203) 409-5444

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   STEX   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    (a) Dismissal of Independent Registered Public Accounting Firm

     

    On July 8, 2026, Streamex Corp. (the “Company”) dismissed CBIZ CPAs P.C. (“CBIZ CPAs”) as its independent registered public accounting firm. The decision to dismiss CBIZ CPAs was approved by the Company’s Audit Committee of the Board of Directors (the “Audit Committee”). As described below, the change in independent registered public accounting firm is not the result of any disagreement with CBIZ CPAs.

     

    As previously disclosed in a Current Report on Form 8-K filed on April 30, 2025, on April 30, 2025 Marcum LLP resigned, and CBIZ CPAs was appointed, as the Company’s independent registered public accounting firm as a result of the acquisition by CBIZ CPAs of the Marcum LLP attest business. The report of CBIZ CPAs on the Company’s financial statements as of and for the fiscal year ended December 31, 2025, did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.

     

    From April 30, 2025 through July 8, 2026, (i) there were no “disagreements” as that term is defined in Item 304(a)(1)(iv) of Regulation S-K promulgated by the Securities and Exchange Commission (“SEC”) pursuant to the Securities Exchange Act of 1934, between the Company and CBIZ CPAs on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of CBIZ CPAs, would have caused CBIZ CPAs to make reference to the subject matter of the disagreement in connection with its report on the financial statements for such year, and (ii) there were no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K except for:

     

    ● The material weakness in the Company’s internal control over financial reporting as initially reported in Item 9A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026, related to the i) inadequate identification, recording and reporting of stock based compensation, ii) ineffective review processes over period end financial disclosure and reporting, including review of IPE (Information Produced by the Entity), (iii) inadequate segregation of duties for transaction posting and processing, and (iv) ineffective review controls over the business combinations and related financial instruments.

     

    The Company has authorized CBIZ CPAs to respond fully to the inquiries of the successor accountant.

     

    The Company has provided CBIZ CPAs with a copy of the foregoing disclosures and has requested that CBIZ CPAs review such disclosures and provide a letter addressed to the SEC as specified by Item 304(a)(3) of Regulation S-K. A copy of CBIZ CPAs’ letter to the SEC is attached to this report as Exhibit 16.1.

     

    (b) Appointment of New Independent Registered Public Accounting Firm

     

    On July 8, 2026, following approval by the Audit Committee, the Company engaged EisnerAmper LLP (“EisnerAmper”) as its new independent registered public accounting firm to succeed CBIZ CPAs.

     

    Neither the Company nor anyone on behalf of the Company has consulted with EisnerAmper during the Company’s fiscal years ended December 31, 2025 and 2024, and in the subsequent interim period through July 8, 2026, regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that EisnerAmper concluded was an important factor considered by the Company in reaching a decision as to an accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K).

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
      Description
    16.1   Letter of CBIZ CPAs P.C. dated July 13, 2026 concerning change in the registrant’s certifying accountant.
    104   Cover Page Interactive Data File (formatted as Inline XBRL).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: July 13, 2026 STREAMEX CORP.
         
      By: /s/ Karl Henry McPhie
      Name: Karl Henry McPhie
      Title: Chief Executive Officer

     

     

     

     

    Get the next $STEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STEX

    DatePrice TargetRatingAnalyst
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. Announces GLDY Now Available for Custody by Inspira Financial, Unlocking Yield-Bearing Gold Exposure for Traditional Finance Investors

    Highlights GLDY Class B shares are now available for custody by Inspira Financial, a qualified custodian under the SEC's Custody Rule. Institutional investors, RIA’s, wealth managers, and advisors who hold client assets within Inspira can now access GLDY through infrastructure they already use.Inspira Financial holds over $63 billion in assets across more than 8 million accounts and has serviced over 1,500 funds. As one of the largest directed custodians in the country, Inspira gives GLDY access to an established institutional custody network with deep reach into the traditional finance capital market, representing a significant step-change in GLDY's addressable distribution.Inspira is the

    7/21/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Announces June 2026 Yield Dividend Distribution for GLDY

    WINTER PARK, Fla., July 17, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the distribution of the fourth yield payment for GLDY, its yield-bearing gold asset, occurred on July 17th, 2026. The distribution covers the period from June 1st through June 30th, 2026. Yield Distribution Details GLDY's real-world yield is generated through Streamex's institutional gold leasing program, with proceeds from the program distributed to GLDY holders in the form of additional GLDY tokens monthly. Each GLDY token is currently earning an ann

    7/17/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Announces 10,000,000 Share Repurchase Program

    WINTER PARK, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced that its board of directors has authorized a new share repurchase program, under which the Company may repurchase, from time to time, up to an aggregate of 10,000,000 shares of the Company’s common stock, par value $0.001 per share, at a price per share up to $2.00, over the next 12 months. Morgan Lekstrom, Executive Chairman of Streamex, said:"The board’s authorization of this repurchase program is a direct expression of our confidence in Streamex’s value and our

    7/7/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Interim Executive Chairman Lekstrom Morgan Lee bought $49,750 worth of shares (50,000 units at $0.99) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    6/15/26 1:21:02 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: Interim Executive Chairman Lekstrom Morgan Lee bought $147,289 worth of shares (47,000 units at $3.13) (SEC Form 4)

    4/A - Streamex Corp. (0001530766) (Issuer)

    5/28/26 9:43:32 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Interim Executive Chairman Lekstrom Morgan Lee bought $49,980 worth of shares (34,000 units at $1.47) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    5/28/26 2:33:28 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matthews Shawn was granted 100,000 shares, increasing direct ownership by 100% to 200,000 units (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    7/10/26 5:00:04 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Gopaul Kevin Roy was granted 100,000 shares, increasing direct ownership by 100% to 200,000 units (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    7/10/26 5:00:03 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Interim Executive Chairman Lekstrom Morgan Lee bought $49,750 worth of shares (50,000 units at $0.99) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    6/15/26 1:21:02 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    SEC Filings

    View All

    Streamex Corp. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    7/13/26 5:19:19 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    5/28/26 4:05:31 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    5/27/26 6:05:10 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. Announces June 2026 Yield Dividend Distribution for GLDY

    WINTER PARK, Fla., July 17, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the distribution of the fourth yield payment for GLDY, its yield-bearing gold asset, occurred on July 17th, 2026. The distribution covers the period from June 1st through June 30th, 2026. Yield Distribution Details GLDY's real-world yield is generated through Streamex's institutional gold leasing program, with proceeds from the program distributed to GLDY holders in the form of additional GLDY tokens monthly. Each GLDY token is currently earning an ann

    7/17/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Announces May 2026 Yield Dividend Distribution for GLDY

    WINTER PARK, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the distribution of the third yield payment for GLDY, its gold-backed, yield-bearing tokenized security, occurred on June 18th, 2026. The distribution covers the period from May 1st through May 31st, 2026. Yield Distribution Details GLDY's real-world yield is generated through Streamex's institutional gold leasing program, with proceeds from the program distributed to GLDY holders in the form of additional GLDY tokens monthly. Each GLDY token is curren

    6/22/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Provides Q1 2026 Earnings and Corporate Update Presentation Recap; Highlights New Partnerships & Key Updates

    WINTER PARK, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company focused on the tokenization of commodity real-world assets, yesterday hosted its Q1 2026 Earnings and Corporate Update Presentation, featuring remarks from Executive Chairman Morgan Lekstrom, Chief Executive Officer Henry McPhie, Chief Financial Officer Christine Plummer, and Chief Investment Officer Mitch Williams. The following is a summary of the key topics covered. Highlights Equity Trust - access to $72B+ and 359,000 U.S. tax-advantaged retirement accounts. An upcoming integration with Equity Trust Company opens GLDY to a distribution channel that prev

    5/21/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

    WINTER PARK, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the appointment of Kori Handy as Vice President of Product and Design. Kori brings 18 years of experience scaling fintech and SaaS platforms from zero to $2B+ in assets under management and more than 200 million users, and joins Streamex at a pivotal moment in the Company's growth trajectory. Highlights Kori brings nearly two decades of product, design, and startup leadership experience building fintech and SaaS platforms used by more than 200 million p

    5/26/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer

    WINTER PARK, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced the appointment of Christine Plummer, former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer of Streamex. In this role, Ms. Plummer is expected to oversee the Company's global finance organization, including financial reporting, regulatory compliance, and financial operations as Streamex continues expanding its institutional platform and launching tokenized commodity products. Henry McPhie, Co-Founder & CEO of Str

    3/16/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors

    WINTER PARK, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today is excited to announce the appointment of Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. and Founder and Chief Investment Officer of Hondius Capital Management, to its Board of Directors. In this role, Mr. Matthews will bring decades of global investment, trading, and executive leadership experience to support Streamex's strategic growth, capital markets initiatives, and governance. He is joining as an independent director. Morgan Lekstrom, Co-Founder & Executive Chairman of Streamex sa

    3/3/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care